CCM
RXDX

CAAS Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

CAAS Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,000
Closed -$1.65M – 993
2022
Q4 		$1.65M Buy
+15,000
New +$973K 0.1% 220
2021
Q2 		– Sell
-15,000
Closed -$274K – 1383
2021
Q1 		$274K Buy
+15,000
New +$310K ﹤0.01% 1010

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's RXDX Position: Q1 2023 in Review

CAAS Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 15,000 shares — an estimated $1.65M sold.

CAAS Capital Management first reported a position in RXDX in Q1 2021 and held it in 2 quarters. The position peaked at $1.65M in Q4 2022. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

  • CAAS Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 15,000 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $1.65M.
  • CAAS Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • CAAS Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $1.65M in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.